|
| 36151992 | Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide. | Pediatr Blood Cancer | 2023 |
| 37910601 | Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma. | Sci Transl Med | 2023 |
| 37505929 | Platinum Sensitivity in <i>IDH1/2</i> Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal. | Cancer Invest | 2023 |
| 37387791 | Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. | Cancer Res Commun | 2023 |
| 36975152 | Use of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors. | Pediatr Blood Cancer | 2023 |
| 36968138 | Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant Glioma. | Cancer Res Commun | 2023 |
| 36753549 | Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy. | Sci Adv | 2023 |
| 36239925 | Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. | Neuro Oncol | 2023 |
| 35273342 | In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. | Leukemia | 2022 |
| 35439320 | TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. | Mol Cancer Ther | 2022 |
| 35561835 | Intrathecal delivery and its applications in leptomeningeal disease. | Adv Drug Deliv Rev | 2022 |
| 35521071 | Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy. | Adv Radiat Oncol | 2022 |
| 35388070 | Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma. | Sci Rep | 2022 |
| 36509072 | Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 36179653 | Polymer nanocarriers for targeted local delivery of agents in treating brain tumors. | Nanotechnology | 2022 |
| 35938683 | Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors. | Biomed Chromatogr | 2022 |
| 35907197 | Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. | J Neurosurg | 2022 |
| 36242713 | The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. | Curr Treat Options Oncol | 2022 |
| 35901163 | Mechanism-based design of agents that selectively target drug-resistant glioma. | Science | 2022 |
| 36128328 | Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. | Oncotarget | 2022 |
| 34861999 | Oncometabolites as Regulators of DNA Damage Response and Repair. | Semin Radiat Oncol | 2022 |
| 34861991 | Introduction: Progress Towards Genomically-directed Radiosensitization. | Semin Radiat Oncol | 2022 |
| 33290275 | MicroRNA miR-24-3p reduces DNA damage responses, apoptosis, and susceptibility to chronic obstructive pulmonary disease. | JCI Insight | 2021 |
| 33781500 | The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance. | Neurosurg Clin N Am | 2021 |
| 34888524 | Correction to 'Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity'. | NAR Cancer | 2021 |
| 34994649 | Clinical Efficacy of Olaparib in <i>IDH1/IDH2-</i>Mutant Mesenchymal Sarcomas. | JCO Precis Oncol | 2021 |
| 34556535 | Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. | J Pharmacol Exp Ther | 2021 |
| 34045730 | Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. | Nat Biomed Eng | 2021 |
| 34316708 | Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity. | NAR Cancer | 2021 |
| 34118569 | Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity. | Transl Oncol | 2021 |
| 33953843 | Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore. | Oncotarget | 2021 |
| 34027408 | Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. | NAR Cancer | 2021 |
| 32494005 | Oncometabolites suppress DNA repair by disrupting local chromatin signalling. | Nature | 2020 |
| 33059370 | Penetrating the brain tumor space with DNA damage response inhibitors. | Neuro Oncol | 2020 |
| 33203878 | Microcephalin 1/BRIT1-TRF2 interaction promotes telomere replication and repair, linking telomere dysfunction to primary microcephaly. | Nat Commun | 2020 |
| 33005030 | LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy. | Nat Cell Biol | 2020 |
| 32528726 | Persistent <i>STAG2</i> mutation despite multimodal therapy in recurrent pediatric glioblastoma. | NPJ Genom Med | 2020 |
| 32506123 | Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery. | Neuro Oncol | 2020 |
| 32413184 | Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer. | Cancer | 2020 |
| 32328653 | Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. | Neuro Oncol | 2020 |
| 31080125 | Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8. | Eur Urol | 2019 |
| 31360809 | Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review. | Adv Radiat Oncol | 2019 |
| 31273061 | Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors. | Cancer Res | 2019 |
| 31439867 | PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. | Nat Commun | 2019 |
| 31177129 | Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis. | Anticancer Res | 2019 |
| 31375752 | Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass Spectrometry. | Sci Rep | 2019 |
| 31371348 | <i>DNMT3A</i> co-mutation in an <i>IDH1</i>-mutant glioblastoma. | Cold Spring Harb Mol Case Stud | 2019 |
| 31592790 | Targeting DNA repair in gliomas. | Curr Opin Neurol | 2019 |
| 30802686 | Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. | Biomaterials | 2019 |
| 31150024 | Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. | Nat Rev Clin Oncol | 2019 |